Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Thioridazine [USAN:USP:INN:BAN]
RN: 50-52-2
UNII: N3D6TG58NI
InChIKey: KLBQZWRITKRQQV-UHFFFAOYSA-N

Note

  • A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.

Molecular Formula

  • C21-H26-N2-S2

Molecular Weight

  • 370.5824
 

Classification Codes

  • Antipsychotic
  • Antipsychotic Agents
  • Central Nervous System Agents
  • Central Nervous System Depressants
  • Dopamine Agents
  • Dopamine Antagonists
  • Drug / Therapeutic Agent
  • Human Data
  • Mutation Data
  • Neurotransmitter Agents
  • Psychotropic Drugs
  • Reproductive Effect
  • Sedative-Hypnotic
  • Tranquilizing Agents

Names and Synonyms

Name of Substance

  • Thioridazine
  • Thioridazine [USAN:USP:INN:BAN]

MeSH Heading

  • Thioridazine

Synonyms

  • (+-)-Thioridazine
  • 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine
  • 10H-Phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylthio)-
  • 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine
  • 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine
  • AI3-51923
  • dl-Thioridazine
  • EINECS 200-044-2
  • HSDB 3189
  • Mallorol
  • Malloryl
  • Meleril
  • Mellaril
  • Mellaril-S
  • Mellerets
  • Mellerette
  • Melleretten
  • Melleril
  • Melleril (liquid)
  • Melleryl
  • Sonapax
  • Thioridazin
  • Thioridazine
  • Thioridazine prolongatum
  • Thioridazinum
  • Thioridazinum [INN-Latin]
  • Thiozine
  • Tioridazina
  • Tioridazina [INN-Spanish]
  • TP-21
  • UNII-N3D6TG58NI

Systematic Names

  • 10H-Phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylthio)-
  • Phenothiazine, 10-((1-methyl-2-piperidyl)ethyl)-2-(methylthio)-
  • Thioridazine

Registry Numbers

CAS Registry Number

  • 50-52-2

FDA UNII

  • N3D6TG58NI

Other Registry Number

  • 57129-06-3

System Generated Number

  • 0000050522

Structure Descriptors

InChI

1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3

InChIKey

KLBQZWRITKRQQV-UHFFFAOYSA-N

Smiles

CN1CCCCC1CCN2c3ccccc3Sc4c2cc(cc4)SC

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
child TDLo oral 25mg/kg (25mg/kg) CARDIAC: CHANGE IN RATE

BEHAVIORAL: TOXIC PSYCHOSIS
American Journal of Diseases of Children. Vol. 130, Pg. 507, 1976.
child TDLo oral 28mg/kg/2W-I (28mg/kg) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) American Journal of Psychiatry. Vol. 143, Pg. 1176, 1985.
human LDLo oral 43mg/kg (43mg/kg) LUNGS, THORAX, OR RESPIRATION: CHRONIC PULMONARY EDEMA

BLOOD: HEMORRHAGE

VASCULAR: REGIONAL OR GENERAL ARTERIOLAR OR VENOUS DILATION
Archives of General Psychiatry. Vol. 34, Pg. 955, 1977.
human TDLo oral 24mg/kg (24mg/kg) AUTONOMIC NERVOUS SYSTEM: PARASYMPATHOLYTIC Anesthesia and Analgesia Vol. 52, Pg. 938, 1973.
man LDLo oral 43mg/kg (43mg/kg) LUNGS, THORAX, OR RESPIRATION: CYANOSIS

CARDIAC: OTHER CHANGES

LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA
Clinical Toxicology. Vol. 7, Pg. 133, 1974.
man TDLo oral 5214mg/kg/5Y- (5214mg/kg) SENSE ORGANS AND SPECIAL SENSES: "RETINAL CHANGES (PIGMENTARY DEPOSITIONS, RETINITIS, OTHER): EYE" American Journal of Psychiatry. Vol. 153, Pg. 1234, 1996.
mouse LD50 intraperitoneal 65mg/kg (65mg/kg)   Journal of Medicinal Chemistry. Vol. 13, Pg. 23, 1970.
mouse LD50 intravenous 53mg/kg (53mg/kg)   French Medicament Patent Document. Vol. #2235M,
mouse LD50 oral 385mg/kg (385mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 15, Pg. 841, 1965.
mouse LD50 subcutaneous 310mg/kg (310mg/kg)   Yakugaku Zasshi. Journal of Pharmacy. Vol. 90, Pg. 800, 1970.
rabbit LD50 intravenous 26mg/kg (26mg/kg)   French Medicament Patent Document. Vol. #2235M,
rabbit LD50 oral 1200mg/kg (1200mg/kg)   French Medicament Patent Document. Vol. #2235M,
rat LD50 intraperitoneal 150mg/kg (150mg/kg) BEHAVIORAL: ANTICONVULSANT

BEHAVIORAL: ANTIPSYCHOTIC
Pharmaceutical Chemistry Journal Vol. 10, Pg. 1001, 1976.
rat LD50 intravenous 71mg/kg (71mg/kg)   Therapie. Vol. 18, Pg. 373, 1963.
rat LD50 oral 995mg/kg (995mg/kg)   Toxicology and Applied Pharmacology. Vol. 18, Pg. 185, 1971.
rat LD50 subcutaneous 640mg/kg (640mg/kg) SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

AUTONOMIC NERVOUS SYSTEM: CENTRAL SYMPATHOLYTIC

BEHAVIORAL: ALTERATION OF CLASSICAL CONDITIONING
Medicinal Chemistry: A Series of Monographs. Vol. 4(2), Pg. 199, 1967.
women TDLo oral 14500mg/kg/15 (14500mg/kg) SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE

SENSE ORGANS AND SPECIAL SENSES: "RETINAL CHANGES (PIGMENTARY DEPOSITIONS, RETINITIS, OTHER): EYE"
Canadian Medical Association Journal. Vol. 132, Pg. 737, 1985.

Physical Properties

Physical Property Value Units Temp (deg C) Source
Melting Point 73 deg C   EXP
pKa Dissociation Constant 9.5 (none)   EXP
log P (octanol-water) 5.9 (none)   EXP
Water Solubility 0.034 mg/L 25 EST
Vapor Pressure 1.42E-09 mm Hg 25 EST
Henry's Law Constant 1.50E-11 atm-m3/mole 25 EST
Atmospheric OH Rate Constant 3.23E-10 cm3/molecule-sec 25 EST

Physical property data is provided to ChemIDplus by SRC, Inc.